TRAW on Nasdaq

Traws Pharma, Inc.

American pharmaceutical preparations company based in Newtown. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Upstream Bio, Inc., Xenetic Biosciences (United States) or TherapeuticsMD, Inc., or pick any stock.

  • TickerTRAW on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersNewtown, United States2
  • Incorporated inDE3
  • Business address12 Penns Trail, Newtown, Pa 189403
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300BRAR7BTG2PIY512
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 29834832

See how the biggest companies compare on our leaderboards

Traws Pharma, Inc. (“Traws,” “we,” or the “Company”) is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-640.7%Operating margin5
328.7%Net margin5
1134.5%Revenue growth, 20255

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Profit100¢$9.2M

Out of $2.8M in revenue.5

Financial statements

Revenue6789105$2.8M in 2025+28% since 2019
0$1.0M$2.0M$3.0M2019: $2.2M$2.2M20192020: $231.0K$231.0K2020−89%2021: $226.0K$226.0K2021−2%2022: $226.0K$226.0K2022+0%2023: $226.0K$226.0K2023+0%2024: $226.0K$226.0K2024+0%2025: $2.8M$2.8M2025+1135%
Operating income6789105-$17.9M in 2025−18% since 2019
-$150.0M-$100.0M-$50.0M02019: -$21.7M-$21.7M20192020: -$25.0M-$25.0M2020+15%2021: -$16.5M-$16.5M2021−34%2022: -$19.6M-$19.6M2022+19%2023: -$20.3M-$20.3M2023+3%2024: -$142.4M-$142.4M2024+601%2025: -$17.9M-$17.9M2025−87%
Net income6789105$9.2M in 2025
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: -$21.5M-$21.5M20192020: -$25.2M-$25.2M2020+17%2021: -$16.2M-$16.2M2021−36%2022: -$19.0M-$19.0M2022+17%2023: -$18.9M-$18.9M2023−0%2024: -$166.5M-$166.5M2024+779%2025: $9.2M$9.2M2025
Fiscal year2019202020212022202320242025
Revenue$2.2M6$231.0K7$226.0K8$226.0K9$226.0K10$226.0K5$2.8M5
Research and development$15.5M6$16.9M7$7.3M8$11.4M9$11.4M9
Operating expenses$16.7M8$19.9M9$20.5M10$142.6M5$20.7M5
Operating income-$21.7M6-$25.0M7-$16.5M8-$19.6M9-$20.3M10-$142.4M5-$17.9M5
Interest
Income before tax-$16.2M8-$19.0M9-$18.9M10-$166.5M5$9.2M5
Income tax$10.0K6$4.0K7
Net income-$21.5M6-$25.2M7-$16.2M8-$19.0M9-$18.9M10-$166.5M5$9.2M5
Earnings per share-$2.177-$0.968-$0.919-$22.5710-$35.215$0.835
Earnings per share (diluted)-$2.177-$0.968-$0.919-$22.5710-$35.215$0.825
Shares (weighted, basic)16.8M shares820.9M shares9839.6K shares101.6M shares58.2M shares5
Shares (weighted, diluted)16.8M shares820.9M shares9839.6K shares101.6M shares58.4M shares5

Compare Traws Pharma, Inc. with another company

Leadership

Who has led Traws Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ramesh Kumar2013–2018
  2. Steven M. Fruchtman2019–2024
  3. Werner Cautreels2024–2025
  4. Iain D. Dukes2025–now

Chair

  1. Iain D. Dukes2024

President

  1. Ramesh Kumar2013–2018
  2. Thomas J. McKearn2013–2016
  3. Steven M. Fruchtman2018–2024

Chief financial officer

  1. Ajay Bansal2013–2016
  2. Mark Patrick Guerin2016–2025
  3. Nora Brennan2025–2026
  4. Charles Nolan Parker2026–now

Chief operating officer

  1. Mark Patrick Guerin2022–2024
  2. Nikolay Savchuk2024–now
201520202025
Board members and other officers (26)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Scientific Officer, VirologyDavid Pauza named Apr 16, 202448
  • DirectorIan Dukes named Apr 16, 202448
  • DirectorM. Theresa Shoemaker named Apr 16, 202448

Former names

  • Onconova Therapeutics, Inc.Mar 4, 2010 to Apr 1, 20243
  • ONCONOVA THERAPEUTICS INCJan 8, 2003 to May 26, 20093

Timeline

  1. Oct 15, 2025New chief executive Iain D. Dukes becomes CEO14
  2. Apr 3, 2024New chief executive Werner Cautreels becomes CEO15
  3. Nov 26, 2019New chief executive Steven M. Fruchtman becomes CEO16
  4. Jul 24, 2013New chief executive Ramesh Kumar becomes CEO17
  5. Dec 22, 1998Founded Traws Pharma, Inc. is founded2

Filings

318 filings to the SEC since October 2021: 10 annual reports, 15 quarterly reports, 82 major events, 120 insider forms, 29 large holders, 1 private raises, 61 other. The latest 20:

  1. Oct 8, 2026PRE 14A EDGAR
  2. Aug 14, 2026SCHEDULE 13G/A EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 14, 202610-Q EDGAR
  5. Aug 14, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G EDGAR
  7. Aug 12, 2026SCHEDULE 13G/A EDGAR
  8. Jul 31, 20268-K EDGAR
  9. Jul 16, 20264 EDGAR
  10. Jul 15, 20264 EDGAR
  11. Jul 15, 20264 EDGAR
  12. Jul 14, 20264 EDGAR
  13. Jul 14, 20264 EDGAR
  14. Jul 14, 20264 EDGAR
  15. Jul 14, 20264 EDGAR
  16. Jul 14, 20264 EDGAR
  17. Jul 14, 20264 EDGAR
  18. Jul 14, 20264 EDGAR
  19. Jul 10, 20268-K EDGAR
  20. Jul 10, 2026424B5 EDGAR

The 318 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 16, 2026OrbiMed Capital GP VIII LLC10% ownerBuy597,729$1.67$998.2KForm 4
Jan 28, 2022OLER ABRAHAM N.SVP Corp Dev & Gen CounselBuy1,500$1.67$2.5KForm 4
Jan 21, 2022OLER ABRAHAM N.SVP Corp Dev & Gen CounselBuy1,500$2.02$3.0KForm 4
Jan 14, 2022OLER ABRAHAM N.SVP Corp Dev & Gen CounselBuy1,500$2.20$3.3KForm 4
Jan 7, 2022OLER ABRAHAM N.SVP Corp Dev & Gen CounselBuy1,500$2.39$3.6KForm 4
Nov 19, 2021OLER ABRAHAM N.SVP Corp Dev & Gen CounselBuy1,000$3.16$3.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 1, 2024Raised $14 million in a private offering of securities Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 34. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Orbimed Advisors LLC1,203,260$1.0M0.0%+597,729
Ally Bridge Group (NY) LLC786,236$663.0K0.9%New
Adage Capital Partners Gp, L.l.c.730,000$615.6K0.0%No change
ADAR1 Capital Management, LLC597,729$504.1K0.0%+443,631
Lynx1 Capital Management LP559,470$471.8K0.1%+544,392
Ikarian Capital, LLC478,142$403.2K0.1%−200,000
Sphera Funds Management Ltd.398,486$336.0K0.0%New
Vanguard Capital Management LLC330,049$278.2K0.0%+274,856
Jane Street Group, LLC216,006$182.2K0.0%+194,765
Alyeska Investment Group, L.P.164,376$138.6K0.0%New
Boothbay Fund Management, LLC133,936$112.9K0.0%−60,600
Geode Capital Management, LLC111,365$93.9K0.0%+34,262
Kynam Capital Management, LP84,400$71.2K0.0%New
Dauntless Investment Group, LLC80,574$67.9K0.1%−336,424
Vanguard Fiduciary Trust Co54,511$46.0K0.0%+22,707
Northern Trust Corp37,454$31.6K0.0%New
State Street Corp25,802$21.8K0.0%No change
XTX Topco Ltd18,092$15.3K0.0%New
BlackRock, Inc.9,941$8.4K0.0%−15
Tower Research Capital LLC (TRC)5,142$4.3K0.0%+1,178
Huntington National Bank4,676$3.9K0.0%New
UBS Group AG3,451$2.9K0.0%−602
Barclays PLC1,947$1.6K0.0%New
SBI Securities Co., Ltd.1,721$1.5K0.0%+1,593
Federation des caisses Desjardins du Quebec500$4140.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59